Space Lab Crystallizes Drugs: A New Era in Medicine?

Varda Space Industries is significantly expanding its ambitions in orbital pharmaceutical manufacturing, following a recent success in crystallizing the HIV drug Ritonavir in space. CEO Will Bruey indicated this is just the beginning for their broad technology.

The company, with backing from Founders Fund, is partnering with United Therapeutics. This collaboration involves sending United's medicines into orbit via uncrewed capsules for processing in microgravity. Varda's sixth mission launched on March 30, 2026, supporting its growing capabilities.

This partnership represents an early commercial effort to develop and return drug molecules from space. Varda notes that reduced gravity can enable the creation of unique molecular structures difficult to replicate on Earth, potentially enhancing drug shelf-life and absorption.

United Therapeutics, specializing in treatments for lung diseases and cancer, will likely send molecular samples of its drugs to space. These will be studied to understand microgravity's effects on molecules, a process distinct from long-term experiments on the International Space Station.

Varda has successfully recovered capsules in Australia and published its Ritonavir crystallization findings in Nature. The company has secured over $53 million in venture capital funding from firms like Founders Fund and Khosla Ventures.